Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

Stylus Medicine, a member of BioSpace’s NextGen Class of 2026, launched in May 2025 to develop new, less complex genetic medicines. The company’s in vivo approach has attracted “intense” interest from ...

In a recent study published in Proceedings of the National Academy of Sciences, researchers engineered Chimeric Antigen Receptor (CAR) CD4 T cells, a technology originally revolutionized for cancer ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

The firm said it expects to file an investigational new drug application for the autologous CAR T-cell therapy TPST-2003 in the US by the end of the year.

CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...

Lymph nodes, considered the command centers of our immune system, often get swollen and stiff when fighting infection. Now, a UC Berkeley-led team of researchers has discovered that this mechanical ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...